Vepoloxamer for vaso-occlusive crises in sickle cell disease – first line
NIHR HSRIC
Record ID 32016000811
English
Authors' recommendations:
Sickle cell disease is an inherited disease that causes red blood cells to develop abnormally. Normal red blood cells are flexible and disc shaped. In sickle cell disease, the cells become rigid and sickle shaped. This causes blockages in blood vessels leading to extreme pain; this is called a vaso-occlusive crisis.
Vepoloxamer is a new drug to treat vaso-occlusive crisis in sickle cell disease. Vepoloxamer is delivered straight into the blood. It enables red blood cells to retain their normal shape and flexibility during a crisis and carry oxygen as normal. When the crisis ends, vepoloxamer is passed out of the body in urine. If licensed in the UK, it could be a new option to treat vaso-occlusive crisis.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/vepoloxamer-for-vaso-occlusive-crises-in-sickle-cell-disease-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Anemia, Sickle Cell
- Erythrocyte Count
- Erythrocytes
- Oxygen
- Pain
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.